Cutting-edge biotech Sangamo stock dives 13% after JPMorgan cites...


Its technology uses proteins called zinc finger nucleases to edit human genes, with the hope that just one procedure could improve patients' lives, and even offer a genetic cure. is developing programs for a range of devastating diseases, and has valuable deals with prominent pharmaceutical companies like Gilead Sciences Inc. Not enough, apparently, for Sangamo to retain its "overweight" rating at JPMorgan, with analyst Eric Joseph downgrading the company to "neutral" early Wednesday and slashing the company's price target by nearly 70%, to $11.



from Biotech News